ASGCT news: Chatter about Vinay Prasad, and newborn screening
The American Society of Gene and Cell Therapy conference is abuzz with discussions surrounding Baby KJ and the absence of Vinay Prasad. Last year, the FDA’s head of biologics, Peter Marks, was a highly anticipated speaker at ASGCT, known for his support of rare disease treatments despite limited evidence. However, Marks has since been dismissed by the Trump administration, leaving many wondering about the stance Vinay Prasad will take on such treatments.
Prasad, a vocal hematologist and critic of the pharmaceutical industry, has stepped into Marks’ role, raising questions about his approach to rare disease therapies. With the gene therapy field eagerly awaiting Prasad’s decisions, the conference is abuzz with speculation and uncertainty.
Unfortunately, the rest of this story is exclusive to STAT+ subscribers. To unlock the full article and gain access to premium analysis, newsletters, events, and news alerts, subscribe to STAT+.
In the meantime, the conference continues to be a hub of knowledge exchange, networking, and debate. Stay tuned for more updates and insights from the American Society of Gene and Cell Therapy conference.
